HLS Therapeutics Inc (FRA:74D)
€ 2.3 0.08 (3.6%) Market Cap: 78.06 Mil Enterprise Value: 126.68 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 66/100

HLS Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 23, 2021 / 01:20PM GMT
Release Date Price: €11.5 (+2.68%)
Rahul Sarugaser
Raymond James Financial, Inc. - Analyst

So my name is Rahul Sarugaser. I'm a MedTech, biotech analyst out of the Raymond James Toronto office. Today we have the pleasure of HLS Therapeutics presenting on the Raymond James Health Innovations Conference, and we have CEO and CFO, respectively, Gilbert Godin and Tim Hendrickson.

This is a Company in which we really have some growing conviction, particularly off the back of the ramp of the commercialization of Vascepa in Canada. The ramp has been well in line with what we've expected despite COVID headwinds and so we are anticipating a relatively good ramp in the back half of the year really be [foreloaded], and that portends, in our view, a really strong 2022. And so this is a story that we are indeed highlighting for our clients.

So, of course, Gilbert does a far better job of telling the story than I do. So I will hand the reins to him. Gilbert?

Gilbert Godin
HLS Therapeutics Inc. - CEO

Good. I bet I could (inaudible) that last statement. Thank you, Rahul, for the kind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot